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Vestibular schwannomas (VS) are characteristically slow-growing, benign tumors that originate from over-proliferation of Schwann cells ensheathing the vestibulocochlear nerve. VS comprise 6-8% of intracranial tumors and are the most common tumor of the cerebellopontine angle [1] .
Due to compression of the vestibulocochlear nerve and the adjacent facial nerve, sensorineuronal hearing loss, aural fullness, tinnitus, dizziness, and imbalance are the most common presenting symptoms. In severe untreated cases, large VS can also compress the brainstem or cerebellum and become life-threatening. Current focus has shifted to optimizing functional outcomes through minimization of cranial nerve damage during VS surgery [2, 3] .
The optimal treatment modality for patients with VS remains under study, but likely depends on several factors including age, preoperative hearing status, tumor size, and location. Patients with small tumors and minimal symptoms are often encouraged to pursue conservative management with a "watch, wait, and scan" approach, which involves serial neuroimaging every 6 to 12 months [4] [5] [6] . Medical management options include chemotherapy and, more recently, immunotherapy [7] . However, more aggressive intervention is necessary for severe or progressive symptoms, or for tumors with observed growth rates exceeding 2.5 mm per year [8, 9] .
Modalities for aggressive management include surgical resection and stereotactic radiation therapy. Radiotherapy may be used as primary therapy (typically in older patients), or as adjuvant therapy in event of recurrence [10] . Surgical approaches for VS include middle cranial fossa (MCF), translabyrinthine (TL), and retrosigmoid approaches (RS). The TL approach is effective in resection of large VS (> 30 mm) but contraindicated if hearing preservation is the goal [11] . In contrast, MCF and RS afford the possibility for preservation of intact preoperative hearing. The choice between MCF and RS is usually determined by personal preference and experience of the attending surgeon. Advantages of RS include a versatility on extracting tumors of all sizes [12] , affording the surgeon a greater view of the brain during surgery, and better access in the medial to lateral dissections [13] . Disadvantages include postsurgical headaches [14] and difficulty in exposing the lateral third portion of the internal auditory canal [15] .
Traditionally, a main determinant of surgery is tumor size. While the MCF approach has been used mostly for intracanalicular tumors, or tumors under 1.5 cm, the RS approach has been used for a wider range of tumor sizes [13, [16] [17] [18] [19] [20] [21] [22] [23] .
The objective of the current study was to perform a systematic review and meta-analysis of hearing preservation rates achieved in patients with sporadic VS who underwent surgical resection via RS craniotomy. In addition, we performed objective assessments of study heterogeneity and bias. Finally, we stratified available outcome data by tumor size to compare hearing preservation rates after RS surgery for intracanalicular, small (0-20 mm), and large (>20 mm) tumors.
MATERIALS AND METHODS

Study eligibility criteria
PubMed and Cochrane databases were used to search for retrospective and prospective studies which reported hearing outcomes in patients who underwent either RS or MCF craniotomies for resection of sporadic VS. Studies which included adjuvant or radiation therapy to the lesion site were excluded. For inclusion, we required that studies reported both pre-and postoperative hearing statuses as defined through either the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) grade [24] or the Gardner-Robertson (GR) grade. Studies that included and did not separately report outcomes for patients with neurofibromatosis type 2 (NF2) were excluded ( Figure S1 ).
Hearing preservation
Serviceable hearing was defined using the 50/50 rule [25] , which refers to a pure-tone auditory threshold of 50 dB or less and speech discrimination score of at least 50% ( Figure S2 ). These criteria correspond to an AAO-HNS grade of A/B or a GR grade of 1/2 hearing. Hearing preservation was defined as the subset of patients with serviceable preoperative hearing in the affected ear who retained serviceable hearing in the affected ear at postoperative follow-up.
Rates of hearing preservation were then determined for each study as the percentage of patients with postoperative hearing preservation among those who had serviceable hearing preoperatively.
Tumor size
When disaggregate data were available, hearing outcomes were tabulated separately based on preoperative tumor size. Three size categories were defined that continually appeared within the classification used in reviewed studies. However, it is important to note that some articles had different guidelines in defining what would be considered as an "intracanalicular tumor."
Intracanalicular tumors were mostly defined as tumors contained within the internal auditory canal without intracisternal involvement (i.e., 0 mm intracisternal diameter) [13, 16, 19, 21] . However, these tumors were also described by Rowed et al. as intracisternal involvements up to but not exceeding 4 mm [20] . Small tumors were defined as those with intracisternal diameters of 0 to 20 mm. Large tumors were defined as those with intracisternal diameters greater than or equal to 20 mm.
Study selection
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed as a basis for screening eligible articles for inclusion in our literature review and meta-analysis [26] . Two authors (VO and CD) independently screened potential articles, identifying through interrogation of the PubMed database by using the search protocol as indicated in Figure S3 . A Cochrane database screening was conducted post-hoc to affirm the inclusion of relevant articles. The final search was performed on November 11, 2017. Sequential screening was performed at the level of article titles, abstracts, and full texts to narrow the volume of articles based upon relevance to our study question.
Statistical analysis
Statistical analysis was conducted using Microsoft® Excel and R v3.4.0. Demographic and clinical measures were tabulated in Excel and simple averages were computed across studies. Hearing preservation rates for patients undergoing RS craniotomy were computed on a study-wise basis as described. Next, aggregate hearing preservation rates and confidence intervals were estimated for all available data using both fixed and random effects models. Next, study heterogeneity was quantified through computation of t 2 , Q, and I 2 statistics. A Wald-type Q statistic was used to assess statistical significance of study heterogeneity. Finally, assessment of study bias was performed using standard funnel plot analysis and an Egger's test for funnel plot asymmetry. For all reported tests, statistical significance was defined using an  criterion of p < 0.05. All described meta-analytic methods were implemented using the meta and lme4 packages for R.
RESULTS
Electronic search and eligibility screening
The results of the study eligibility screening process are summarized in Figure S3 . A total of 313 de-duplicated articles were identified through our database search, of which 16 met eligibility criteria and were included in our analysis. These studies reported hearing outcomes after RS craniotomy published between 1997 and 2016. Among the 16 reviewed studies, 15 were retrospective studies [13, 14, 16, 17, [19] [20] [21] [22] [23] [27] [28] [29] [30] [31] [32] and 1 was prospective [18] . Table 1 summarizes demographic and clinical variables for patient cohorts across the 16 reviewed studies. In total, reviewed studies reported outcomes for 1,828 patients who underwent RS craniotomy for sporadic VS. Average age at surgery ranged from 45 to 51 years and was 48 years on average. In terms of gender composition, the percentage of female patients in study cohorts ranged from 43% to 82% and averaged 54%. Tumor diameters ranged from 0 mm (i.e., intracanalicular) to 24.1 mm, and averaged 12 mm across studies. Follow-up times ranged from 1 to 56.7 months. Average study follow-up time was 21 months. Among the 1,828 patients 
Patient characteristics
Hearing preservation rates after RS craniotomy
Rates of hearing preservation after RS craniotomy of sporadic VS are summarized in Figure 1 .
Hearing preservation rates ranged from 12% to 79% across reviewed studies. Under a fixed effects model assuming no cross-study variability, the aggregate hearing preservation rate was 23% (95% CI: [21%, 26%]). Under a random effects model, the aggregate hearing preservation rate was 37% (95% CI: [25%, 52%]).
Study heterogeneity
Marked variability in hearing preservation rates was observed across individual studies and is depicted graphically on forest plot analysis (Figure 1 ). Quantitative metrics all confirmed the presence of significant study heterogeneity (I 2 = 92%, τ 2 = 1.22, P < 0.01; Q = 206.47, P = < 0.0001). reported higher hearing preservation rates than the fixed effects estimate. Egger's test was positive for significant funnel plot asymmetry (t(14) = 2.9, P = 0.01).
Study bias assessment
Effect of tumor size on hearing preservation rates
Eight studies provided patient hearing data disaggregated by preoperative tumor size ( Table 2) .
Disaggregate data were available for a total of 299 cases, including 94 intracanalicular tumors, 139 small tumors (0-20 mm), and 66 large tumors ( 20 mm). Hearing preservation rates among patients falling within these tumor subgroups were 59%, 37%, and 11%, respectively. The overall average hearing preservation rate was 38% across all patients with available sizestratified data.
DISCUSSION
Summary
We conducted a meta-analysis of published studies reporting hearing outcomes for patients with sporadic VS undergoing surgical resection via the RS approach. Sixteen studies met eligibility criteria comprising a total of 1,249 patients with serviceable preoperative hearing in the affected ear, from whom postoperative hearing preservation could be evaluated. Results from the metaanalysis revealed significant cross-study heterogeneity, with rates of hearing preservation ranging from 12 to 79% across studies. Aggregate hearing preservation was 23% under a fixed effects model and 37% allowing for random study effects. Clear systematic bias was also apparent, with disproportionate numbers of (mostly smaller) studies reporting hearing preservation rates markedly higher than the aggregate estimates. As expected, rates of hearing preservation were also strongly dependent on preoperative tumor size, with rates of 59%, 37% and 11%, observed for intracanalicular, small, and large (>20 mm) tumors, respectively. To our knowledge, this is first study to estimate hearing preservation rates in sporadic VS patients after RS surgery using a robust meta-analytical framework.
Study heterogeneity
Through the means of a forest plot, studies with a small sample size and therefore low power are given more weight than usual. This allows for a greater inclusion of articles in the overall determination of the average hearing preservation for the RS approach among VS patients. Here we looked at the overall hearing preservation found across 1,249 patients and found a proportion of 0.23 for the fixed effects model and a proportion of 0.37 for the random effects model. The fixed effects model depended on the variance between all the subjects within the pooled articles.
The random effects model, on the other hand, depended on both the variance within and between studies. In other words, differences between protocol and surgery experience were better accounted for within the random effects model than with the fixed effects model. Both models revealed a low hearing preservation rate within the current literature. Sanna et al., conducted a study which compared the hearing preservation rates across MCF, TL, and RS surgery approaches. When using the hearing preservation guidelines of AAO-HNS, a value of 0.32 was found for their retrospective case review of their institution, which is close to the value of 0.37 obtained from our meta-analysis [21] . With results within the same regional proportion, the hearing preservation rate expected for patients undergoing the RS approach for VS can be further elucidated. 
Assessment of study bias
Apparent publication bias was also assessed within the included articles of the meta-analysis.
Through funnel plot analysis, results suggested multiple positively skewed proportions for hearing preservation. In other words, many low-powered studies reported high hearing preservation rates. This could be explained by the pressure to find significant findings deemed suitable of being published. Additionally, conducting small, retrospective reviews do not require as much time or resources in comparison to conducting controlled, randomized trials. Based on the lack of heterogeneity and the prevalence of low-powered studies with high proportions of hearing preservation, the true hearing preservation rate is not actually 0.37. In fact, the true rate is closer to the value given by the fixed effects model rather than that of the random effects.
Assessment of tumor size
In terms of tumor size, the mean size examined in this meta-analysis was 12 mm in diameter ( Table 2) . Although many articles have noted that the RS approach was used mostly for larger tumors, the current scientific literature provided examples for the use of RS on intracranial and on extrameatal tumors less than 2mm in diameter as well [16, 18, 23] . When separating hearing preservation into different subsets of tumor size, hearing preservation was shown to be higher in patients with small, intracanalicular tumors in comparison to patients with extrameatal tumors 20 mm or larger. Tumor size, however, is not the only factor implicated in hearing loss management.
According to other studies, loss of hearing can occur even without measurable growth of the VS.
This phenomenon is hypothesized to be caused by a build-up of tumor protein in the auditory canal [33, 34] . 
Factors involved in deciding treatment type
In determining the proper treatment strategy per situation of individual patients, other factors should also be incorporated in the overall decision. In terms of the RS approach, potential postoperative symptoms include headaches [13] , CSF leaks [35] , and labyrinth injuries [36, 37] . CSF leaks were noted to affect 2 to 18% of patients who underwent the RS approach for VS [1, 21, 35] . Treatment options outside the realm of traditional surgery carry their own consequences.
As shown by the work of Cauley et al., exposure to radiosurgery potentially increases patients' potential to develop hydrocephalus [38] . Ultimately, every treatment strategy has its associated risks and should be accounted for when making final decisions for treatment.
Limitations
In retrospect, although PubMed and Cochrane were used in this study, more databases could have been used to include more articles in the literature review. If we were to repeat this study again, we would implement similar search terms in more databases to see if any relevant articles may have been missed.
Another limitation was the inconsistency of defining the parameters of "intracanalicular tumor." given patient without considerable uncertainty from random effects. Such factors include patient characteristics including age and co-morbidity burden, expertise of the surgical team, tumor size and location, specific surgical protocols, resources, and experience of the institution, and other factors. We attempted to quantify the presence of these factors through quantitative assessment of study heterogeneity. Not surprisingly, we found marked heterogeneity with wide ranges in hearing preservation across studies. Despite small sample sizes in several studies (Figure 2) , 92% of the variability in hearing preservation was attributable to cross-study effects rather than chance.
Observing such marked cross-study heterogeneity would favor the adoption of a random effects model, which yielded an estimated aggregate hearing preservation rate of 37% compared to 23% with a fixed effects model. However, these hearing preservation rates are called into question given the observation of significant study bias involving a preponderance of smaller studies reporting favorable hearing preservation relative to the aggregate rates under either model. This presence of confounding factors was attempted to be addressed by the inclusion of the random effects model. Additionally, all tumor sizes were incorporated in this study. Although the focus was not on a certain subset of tumor size, it is important to acknowledge that the proportion of 0.37 does not reflect hearing preservation for all VS sizes of people but instead of the accumulated rate of hearing preservation across all tumor sizes. Lastly, hearing preservation is not the only factor needed to be accounted for in VS treatment; varying situational factors, such as tumor location need to be incorporated as well. Finally, Vestibular schwannomas, known to be bilateral and aggressive, are caused by a chromosome 22q11 deletion [39] . Due to the Interestingly, the patient also noted dysgeusia, which was characterized as a loss in taste when eating. After one year of follow-up, the patient reported improved hearing and lack of tinnitus.
Conclusions
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